[ad_1]
BREAKING NEWS: FDA seeks probe into communications between its staff and Biogen after controversial approval of Alzheimer’s drug
- FDA commissioner Janet Woodcock has asked for a probe into her staff’s communications with Biogen
- Biogen’s Aduhelm received FDA approval for Alzhiemer’s disease in early June despite limited data that it worked in clinical trials
The U.S. Food and Drug Administration (FDA) is asking for a federal investigation into its approval of a controversial Alzheimer’s drug.
Janet Woodcock, acting commissioner of the FDA, has asked for a probe into communications between FDA staff and Biogen representatives in the lead up to the approval of Aduhelm, the company’s Alzheimer’s drug.
The drug received FDA approval on June 7 despite limited data that it worked in clinical trials.
The story was first reported by The Wall Street Journal.
This is a breaking news story and will be updated.
Advertisement
[ad_2]
